Twist Bioscience (TWST) Asset Writedowns and Impairment (2019 - 2024)

Twist Bioscience has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting $293000.0 for Q3 2024.

• In Q3 2024, Asset Writedowns and Impairment fell 80.89% year-over-year to $293000.0; the TTM figure through Sep 2024 stood at $940000.0 (down 63.47% YoY), while the FY2025 annual figure was -$20000.0, down 102.13% from the prior year.
• Asset Writedowns and Impairment improved to $293000.0 in Q3 2024, from $144000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for TWST reached as high as $17.5 million in Q3 2022 and fell as low as -$1.0 million in Q2 2020.
• The 5-year median for Asset Writedowns and Impairment is $332000.0 (2023), against an average of $1.3 million.
• Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 1379.41% — and 2023, when it sank 91.26%.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $248000.0 in 2020, then soared by 373.39% to $1.2 million in 2021, then sank by 78.36% to $254000.0 in 2022, then fell by 2.36% to $248000.0 in 2023, then climbed by 18.15% to $293000.0 in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $293000.0, $144000.0, and $255000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.